You used it every day for six months. You bought the second bottle, then the third. Your part looks the same, and now you are wondering whether the problem is your consistency, your genetics, or the medication.
It is probably none of those. There is a specific, well-documented reason minoxidil fails for a subset of women, and it has nothing to do with how faithfully you applied it.
Minoxidil is a prodrug that needs conversion by minoxidil sulfate
Here is the fact that reframes everything.
The minoxidil in the bottle is inactive. It is a prodrug, meaning it arrives in a dormant form and requires conversion inside your body before it can do anything. The active compound is minoxidil sulfate, and that conversion happens in the outer root sheath of your hair follicle, performed by an enzyme called sulfotransferase, specifically SULT1A1.
No conversion, no drug. You can apply minoxidil twice daily for a year with perfect consistency, and if your follicles lack sufficient sulfotransferase activity, most of what you applied never becomes the compound that stimulates growth.
This is not a theory about absorption or a story about your scalp being too oily. It is enzymology, and it explains the number that frustrates every woman who has tried this medication.
Why the minoxidil response rates are what they are
Minoxidil has always had a modest response rate, and the published figures are worth seeing plainly.
Research on topical minoxidil puts overall efficacy at roughly 30 to 40% of patients (Goren et al., 2014). For women specifically, the picture is narrower. A review of studies on 2% minoxidil monotherapy in women found moderate regrowth in only 13 to 20% of female patients, with 5% minoxidil used off-label raising responders to as much as 40% (Roberts et al., 2014).
Sit with that. The most prescribed hair loss treatment in the world does nothing meaningful for the majority of women who use it. Not because they used it wrong. Because a majority never converted it.
Researchers built a diagnostic around this. Sulfotransferase activity measured in plucked hair follicles predicts minoxidil response, and an analysis of multiple studies found the enzyme test ruled out 95.9% of non-responders (Goren et al., 2015). The biology is settled enough to test for.
Are you actually a minoxidil non-responder?
Before we get to the enzyme, rule out the ordinary explanations. I check these first with every patient.
You have not given it long enough. Minoxidil takes three to six months to show visible change, and the first eight weeks often bring increased shedding as follicles re-enter the growth phase. If you are at week ten and discouraged, you are early, not failing.
The concentration is too low. Two percent underperforms in women. Most of my patients need more, and our serum uses 7.5% topical minoxidil, among the highest concentrations available.
The vehicle is fighting you. Drugstore minoxidil is typically suspended in propylene glycol and alcohols, which irritate many scalps. An irritated scalp leads to inconsistent application, and inconsistent application looks identical to non-response.
Something else is driving the loss. Minoxidil treats the follicle. It does not correct low ferritin, thyroid dysfunction, or a nutritional gap. If your labs were never checked, the medication may be working against a headwind it cannot fix.
You stopped and restarted. Gains from minoxidil reverse within months of stopping. A stop-start pattern reads as failure when it is discontinuation.
Clear all five and you are left with the enzyme.
What raises sulfotransferase activity
This is where tretinoin enters, and where I want to be precise, because this finding gets exaggerated across the internet.
Sharma and colleagues studied twenty patients with androgenetic alopecia, ten men and ten women, applying 0.1% topical tretinoin to a marked scalp area for five days. They measured follicular sulfotransferase before and after. Tretinoin increased enzyme activity, and among the subjects initially predicted to be minoxidil non-responders, 43% crossed the threshold into predicted responder status (Sharma et al., 2019).
The honest caveats. The study was small, ran five days, and measured enzyme activity rather than photographed regrowth. It is a mechanism study, not an efficacy trial. Anyone quoting it as proof that tretinoin guarantees a response is overselling it.
What it does establish is a plausible, measurable pathway. Tretinoin appears to act on the specific enzymatic step where minoxidil fails, which is a more interesting claim than the older explanation that retinoids simply help the drug penetrate. Earlier work did show tretinoin increases percutaneous absorption of minoxidil (Ferry et al., 1990), so both effects may contribute. Better delivery and better conversion address different halves of the same problem.
This is why tretinoin sits in our serum alongside 7.5% minoxidil rather than being sold as a separate step. The two ingredients are not a stack for the sake of a longer label. One converts and activates what the other delivers.
What to do if minoxidil failed you
Non-response to one formulation is information, not a verdict. It tells you the delivery, the concentration, or the conversion needs to change. It does not tell you your follicles are finished.
The options that address enzyme non-response directly:
Add tretinoin to the topical. Targets the conversion step and the absorption step at once.
Raise the concentration. More substrate matters when conversion is inefficient. Seven and a half percent is a different proposition than the 2% on the drugstore shelf.
Consider the oral route. Low-dose oral minoxidil bypasses topical absorption entirely, though it still depends on sulfotransferase for activation and requires physician oversight.
Add a mechanism that does not depend on minoxidil. DHT is the driver in androgenetic alopecia, and a DHT blocker works on a completely separate pathway. Topical dutasteride does not require sulfation to work. If you are pregnant, trying to conceive, or could become pregnant, dutasteride is not an option for you, and we route you to our foundational formula instead.
Run the labs. Ferritin, thyroid, and vitamin D belong in this conversation before anyone concludes a medication failed.
The women who succeed after a failed minoxidil attempt are rarely the ones who tried harder with the same product. They are the ones who changed the variable that was actually broken.
Minoxidil not working means the protocol was wrong for your biology. Real regrowth is possible with the right treatment, and finding it starts with knowing which step failed.
Get My Formula
Frequently asked questions
Why is minoxidil not working for me? The most common reasons are insufficient time on treatment, a concentration too low for female pattern loss, an irritating vehicle causing inconsistent use, an untreated underlying cause such as low ferritin or thyroid dysfunction, or low follicular sulfotransferase activity, the enzyme that converts minoxidil into its active form.
What is minoxidil resistance? The term usually describes non-response driven by low sulfotransferase enzyme activity in the hair follicle. Minoxidil is a prodrug that requires this enzyme to convert it into minoxidil sulfate. Without adequate conversion, the applied medication cannot stimulate the follicle.
Can you become a minoxidil responder? Research suggests enzyme activity is modifiable. In one small study, five days of topical tretinoin raised follicular sulfotransferase activity, and 43% of predicted non-responders crossed into predicted responder status. This measured enzyme activity rather than regrowth, so it points to a pathway rather than a guarantee.
How long before I decide minoxidil is not working? Give it a full six months of consistent daily use at an appropriate concentration before concluding non-response, and expect increased shedding in the first two months as follicles re-enter growth. Reassess with a prescriber rather than stopping on your own.
References
Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 2014;27(3):171-173. PMID: 24283387.
Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatologic Therapy. 2014;27(4):252-254. PMID: 24773771.
Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. 2015;28(1):13-16. PMID: 25112173.
Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy. 2019;32(3):e12915. PMID: 30974011.
Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clinical Pharmacology & Therapeutics. 1990;47(4):439-446. PMID: 2328551.
Minoxidil is one of the most widely used treatments for hair loss. It has been used for decades and is approved for treating androgenetic alopecia (pattern hair loss) in both men and women.
But many people notice something frustrating: Minoxidil simply doesn’t work for them.
This phenomenon is known as minoxidil resistance. Research suggests that 30–40% of people may be poor responders to topical minoxidil, meaning their hair follicles do not effectively convert the drug into its active form. Understanding why this happens is essential for choosing the right treatment strategy.
Why might Minoxidil resistance happen in the first place?
Minoxidil resistance occurs when hair follicles cannot properly activate minoxidil, preventing the medication from stimulating hair growth. Minoxidil itself is actually a prodrug, meaning it must be converted into its active form—minoxidil sulfate—inside the scalp.
This conversion is performed by an enzyme called sulfotransferase (SULT1A1).
If someone has low sulfotransferase activity in their scalp, minoxidil may produce little or no benefit.
The Sulfotransferase Enzyme and Hair Growth
The enzyme sulfotransferase plays a critical role in determining whether minoxidil works. Hair follicles with higher sulfotransferase activity are much more likely to respond to treatment.
Research has shown:
High enzyme activity → strong response to minoxidil
Low enzyme activity → poor response or “minoxidil resistance”
A study published in the Journal of Investigative Dermatology found that sulfotransferase activity can predict minoxidil response with up to 90% accuracy.
This means the effectiveness of minoxidil is partly determined by your scalp biology and genetics.
Signs Minoxidil May Not Be Working
Some people stop treatment too early, while others truly have resistance.
Signs you may be a poor responder to minoxidil include:
No visible hair density improvement after 6–12 months
Continued hair thinning despite consistent use
Minimal or no shedding phase when starting treatment
Hair follicles appearing unchanged on scalp imaging
Because hair growth cycles are slow, most physicians recommend at least six months of consistent treatment before evaluating response.
Can Minoxidil Resistance Be Overcome?
In most cases, YES.
Several strategies can improve response to minoxidil.
1. Adding Tretinoin
Tretinoin (a vitamin A derivative) can increase sulfotransferase activity in the scalp, potentially converting non-responders into responders. Studies show that combining minoxidil with tretinoin may significantly improve results.
2. Microneedling
Microneedling stimulates growth factors and may enhance minoxidil penetration. Clinical studies show that microneedling combined with minoxidil produces better hair regrowth than minoxidil alone.
3. Switching to Oral Minoxidil
Low-dose oral minoxidil bypasses some of the limitations of topical activation and has become increasingly popular in dermatology and hair restoration clinics. Because the drug is processed systemically, it may help people who do not respond to topical formulations.
4. Using Combination Therapies
Hair loss is often driven by multiple biological pathways. Many physicians now prescribe combination treatments that may include:
Minoxidil
Anti-androgens (such as spironolactone or finasteride/dutasteride)
Retinoids
Growth-supporting peptides and scalp therapies
Treating only one pathway often leads to suboptimal results.
Why Early Treatment Matters
Hair follicles gradually shrink during androgenetic alopecia. The earlier treatment begins, the more follicles remain capable of regrowth.
Waiting too long can lead to permanent follicle miniaturization, where medications have limited ability to restore density. This is why early diagnosis and physician-guided treatment plans are so important.
A Modern Approach to Hair Loss Treatment
Many over-the-counter products rely solely on standard minoxidil formulas. Newer physician-guided approaches often combine multiple mechanisms of action to improve outcomes, especially in patients with suspected minoxidil resistance. This may include prescription-strength formulations that support follicle signaling, improve drug activation in the scalp, and address hormonal contributors to hair thinning.
Platforms like Hair Cultivated offer physician-designed hair growth treatments for women that combine clinically supported ingredients and customized prescriptions to help support healthier, fuller hair.
Learn more about Minoxidil Resistance >>
You used it every day for six months. You bought the second bottle, then the third. Your part looks the same, and now you are wondering whether the problem is your consistency, your genetics, or the medication.
It is probably none of those. There is a specific, well-documented reason minoxidil fails for a subset of women, and it has nothing to do with how faithfully you applied it.
Minoxidil is a prodrug that needs conversion by minoxidil sulfate
Here is the fact that reframes everything.
The minoxidil in the bottle is inactive. It is a prodrug, meaning it arrives in a dormant form and requires conversion inside your body before it can do anything. The active compound is minoxidil sulfate, and that conversion happens in the outer root sheath of your hair follicle, performed by an enzyme called sulfotransferase, specifically SULT1A1.
No conversion, no drug. You can apply minoxidil twice daily for a year with perfect consistency, and if your follicles lack sufficient sulfotransferase activity, most of what you applied never becomes the compound that stimulates growth.
This is not a theory about absorption or a story about your scalp being too oily. It is enzymology, and it explains the number that frustrates every woman who has tried this medication.
Why the minoxidil response rates are what they are
Minoxidil has always had a modest response rate, and the published figures are worth seeing plainly.
Research on topical minoxidil puts overall efficacy at roughly 30 to 40% of patients (Goren et al., 2014). For women specifically, the picture is narrower. A review of studies on 2% minoxidil monotherapy in women found moderate regrowth in only 13 to 20% of female patients, with 5% minoxidil used off-label raising responders to as much as 40% (Roberts et al., 2014).
Sit with that. The most prescribed hair loss treatment in the world does nothing meaningful for the majority of women who use it. Not because they used it wrong. Because a majority never converted it.
Researchers built a diagnostic around this. Sulfotransferase activity measured in plucked hair follicles predicts minoxidil response, and an analysis of multiple studies found the enzyme test ruled out 95.9% of non-responders (Goren et al., 2015). The biology is settled enough to test for.
Are you actually a minoxidil non-responder?
Before we get to the enzyme, rule out the ordinary explanations. I check these first with every patient.
You have not given it long enough. Minoxidil takes three to six months to show visible change, and the first eight weeks often bring increased shedding as follicles re-enter the growth phase. If you are at week ten and discouraged, you are early, not failing.
The concentration is too low. Two percent underperforms in women. Most of my patients need more, and our serum uses 7.5% topical minoxidil, among the highest concentrations available.
The vehicle is fighting you. Drugstore minoxidil is typically suspended in propylene glycol and alcohols, which irritate many scalps. An irritated scalp leads to inconsistent application, and inconsistent application looks identical to non-response.
Something else is driving the loss. Minoxidil treats the follicle. It does not correct low ferritin, thyroid dysfunction, or a nutritional gap. If your labs were never checked, the medication may be working against a headwind it cannot fix.
You stopped and restarted. Gains from minoxidil reverse within months of stopping. A stop-start pattern reads as failure when it is discontinuation.
Clear all five and you are left with the enzyme.
What raises sulfotransferase activity
This is where tretinoin enters, and where I want to be precise, because this finding gets exaggerated across the internet.
Sharma and colleagues studied twenty patients with androgenetic alopecia, ten men and ten women, applying 0.1% topical tretinoin to a marked scalp area for five days. They measured follicular sulfotransferase before and after. Tretinoin increased enzyme activity, and among the subjects initially predicted to be minoxidil non-responders, 43% crossed the threshold into predicted responder status (Sharma et al., 2019).
The honest caveats. The study was small, ran five days, and measured enzyme activity rather than photographed regrowth. It is a mechanism study, not an efficacy trial. Anyone quoting it as proof that tretinoin guarantees a response is overselling it.
What it does establish is a plausible, measurable pathway. Tretinoin appears to act on the specific enzymatic step where minoxidil fails, which is a more interesting claim than the older explanation that retinoids simply help the drug penetrate. Earlier work did show tretinoin increases percutaneous absorption of minoxidil (Ferry et al., 1990), so both effects may contribute. Better delivery and better conversion address different halves of the same problem.
This is why tretinoin sits in our serum alongside 7.5% minoxidil rather than being sold as a separate step. The two ingredients are not a stack for the sake of a longer label. One converts and activates what the other delivers.
What to do if minoxidil failed you
Non-response to one formulation is information, not a verdict. It tells you the delivery, the concentration, or the conversion needs to change. It does not tell you your follicles are finished.
The options that address enzyme non-response directly:
Add tretinoin to the topical. Targets the conversion step and the absorption step at once.
Raise the concentration. More substrate matters when conversion is inefficient. Seven and a half percent is a different proposition than the 2% on the drugstore shelf.
Consider the oral route. Low-dose oral minoxidil bypasses topical absorption entirely, though it still depends on sulfotransferase for activation and requires physician oversight.
Add a mechanism that does not depend on minoxidil. DHT is the driver in androgenetic alopecia, and a DHT blocker works on a completely separate pathway. Topical dutasteride does not require sulfation to work. If you are pregnant, trying to conceive, or could become pregnant, dutasteride is not an option for you, and we route you to our foundational formula instead.
Run the labs. Ferritin, thyroid, and vitamin D belong in this conversation before anyone concludes a medication failed.
The women who succeed after a failed minoxidil attempt are rarely the ones who tried harder with the same product. They are the ones who changed the variable that was actually broken.
Minoxidil not working means the protocol was wrong for your biology. Real regrowth is possible with the right treatment, and finding it starts with knowing which step failed.
Get My Formula
Frequently asked questions
Why is minoxidil not working for me? The most common reasons are insufficient time on treatment, a concentration too low for female pattern loss, an irritating vehicle causing inconsistent use, an untreated underlying cause such as low ferritin or thyroid dysfunction, or low follicular sulfotransferase activity, the enzyme that converts minoxidil into its active form.
What is minoxidil resistance? The term usually describes non-response driven by low sulfotransferase enzyme activity in the hair follicle. Minoxidil is a prodrug that requires this enzyme to convert it into minoxidil sulfate. Without adequate conversion, the applied medication cannot stimulate the follicle.
Can you become a minoxidil responder? Research suggests enzyme activity is modifiable. In one small study, five days of topical tretinoin raised follicular sulfotransferase activity, and 43% of predicted non-responders crossed into predicted responder status. This measured enzyme activity rather than regrowth, so it points to a pathway rather than a guarantee.
How long before I decide minoxidil is not working? Give it a full six months of consistent daily use at an appropriate concentration before concluding non-response, and expect increased shedding in the first two months as follicles re-enter growth. Reassess with a prescriber rather than stopping on your own.
References
Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 2014;27(3):171-173. PMID: 24283387.
Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatologic Therapy. 2014;27(4):252-254. PMID: 24773771.
Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. 2015;28(1):13-16. PMID: 25112173.
Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy. 2019;32(3):e12915. PMID: 30974011.
Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clinical Pharmacology & Therapeutics. 1990;47(4):439-446. PMID: 2328551.
Minoxidil is one of the most widely used treatments for hair loss. It has been used for decades and is approved for treating androgenetic alopecia (pattern hair loss) in both men and women.
But many people notice something frustrating: Minoxidil simply doesn’t work for them.
This phenomenon is known as minoxidil resistance. Research suggests that 30–40% of people may be poor responders to topical minoxidil, meaning their hair follicles do not effectively convert the drug into its active form. Understanding why this happens is essential for choosing the right treatment strategy.
Why might Minoxidil resistance happen in the first place?
Minoxidil resistance occurs when hair follicles cannot properly activate minoxidil, preventing the medication from stimulating hair growth. Minoxidil itself is actually a prodrug, meaning it must be converted into its active form—minoxidil sulfate—inside the scalp.
This conversion is performed by an enzyme called sulfotransferase (SULT1A1).
If someone has low sulfotransferase activity in their scalp, minoxidil may produce little or no benefit.
The Sulfotransferase Enzyme and Hair Growth
The enzyme sulfotransferase plays a critical role in determining whether minoxidil works. Hair follicles with higher sulfotransferase activity are much more likely to respond to treatment.
Research has shown:
High enzyme activity → strong response to minoxidil
Low enzyme activity → poor response or “minoxidil resistance”
A study published in the Journal of Investigative Dermatology found that sulfotransferase activity can predict minoxidil response with up to 90% accuracy.
This means the effectiveness of minoxidil is partly determined by your scalp biology and genetics.
Signs Minoxidil May Not Be Working
Some people stop treatment too early, while others truly have resistance.
Signs you may be a poor responder to minoxidil include:
No visible hair density improvement after 6–12 months
Continued hair thinning despite consistent use
Minimal or no shedding phase when starting treatment
Hair follicles appearing unchanged on scalp imaging
Because hair growth cycles are slow, most physicians recommend at least six months of consistent treatment before evaluating response.
Can Minoxidil Resistance Be Overcome?
In most cases, YES.
Several strategies can improve response to minoxidil.
1. Adding Tretinoin
Tretinoin (a vitamin A derivative) can increase sulfotransferase activity in the scalp, potentially converting non-responders into responders. Studies show that combining minoxidil with tretinoin may significantly improve results.
2. Microneedling
Microneedling stimulates growth factors and may enhance minoxidil penetration. Clinical studies show that microneedling combined with minoxidil produces better hair regrowth than minoxidil alone.
3. Switching to Oral Minoxidil
Low-dose oral minoxidil bypasses some of the limitations of topical activation and has become increasingly popular in dermatology and hair restoration clinics. Because the drug is processed systemically, it may help people who do not respond to topical formulations.
4. Using Combination Therapies
Hair loss is often driven by multiple biological pathways. Many physicians now prescribe combination treatments that may include:
Minoxidil
Anti-androgens (such as spironolactone or finasteride/dutasteride)
Retinoids
Growth-supporting peptides and scalp therapies
Treating only one pathway often leads to suboptimal results.
Why Early Treatment Matters
Hair follicles gradually shrink during androgenetic alopecia. The earlier treatment begins, the more follicles remain capable of regrowth.
Waiting too long can lead to permanent follicle miniaturization, where medications have limited ability to restore density. This is why early diagnosis and physician-guided treatment plans are so important.
A Modern Approach to Hair Loss Treatment
Many over-the-counter products rely solely on standard minoxidil formulas. Newer physician-guided approaches often combine multiple mechanisms of action to improve outcomes, especially in patients with suspected minoxidil resistance. This may include prescription-strength formulations that support follicle signaling, improve drug activation in the scalp, and address hormonal contributors to hair thinning.
Platforms like Hair Cultivated offer physician-designed hair growth treatments for women that combine clinically supported ingredients and customized prescriptions to help support healthier, fuller hair.
Learn more about Minoxidil Resistance >>
ABOUT THE AUTHOR
Written by Dr. Kira Mengistu, MD — Harvard-trained physician and co-founder and Chief Medical Officer of Hair Cultivated. Dr. Mengistu experienced hair loss herself, and built Hair Cultivated to give women the clinical-grade treatment she couldn’t find.
Written by Dr. Kira Mengistu, MD — Harvard-trained physician and co-founder and Chief Medical Officer of Hair Cultivated. Dr. Mengistu experienced hair loss herself, and built Hair Cultivated to give women the clinical-grade treatment she couldn’t find.
